Extremities The commercialization of Bioretec’s RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement byJosh SandbergNovember 20, 2024
Spine Inside information: Bioretec updates its product development strategy by accelerating the product development of RemeOs™ Spinal Interbody Cage byJosh SandbergOctober 4, 2024
Financial Bioretec Ltd’s half-year report January-June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results byJosh SandbergAugust 15, 2024
Extremities Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures byTim AllenJune 19, 2024
Regulatory Spine Top Stories Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ Spinal Interbody Cage byJosh SandbergMarch 14, 2024
Extremities Inside information: Bioretec enters into the U.S. distribution agreement with Spartan Medical for the RemeOs™ screws byJosh SandbergSeptember 12, 2023
Extremities Spine Bioretec unveils its revitalized Scientific Advisory Board (SAB), focusing on driving innovations in orthopedic implants byJosh SandbergAugust 16, 2023
Extremities Bioretec Ltd invests in a CNC machining center to increase the RemeOs™ production capacity byJosh SandbergJune 13, 2023
Extremities Regulatory Top Stories Bioretec is the first in the world to receive FDA approval for a bioresorbable metal product byJosh SandbergMarch 30, 2023
Regulatory Top Stories Bioretec updates its estimate of the timing for approval of the CE mark for the RemeOs™ trauma screw byJosh SandbergNovember 4, 2022
